tetano
Editor, Senior Moderator
Sci Adv
. 2020 Oct 9;eabc9999.
doi: 10.1126/sciadv.abc9999. Online ahead of print.
Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals
Yuanmei Zhu[SUP] #[/SUP][SUP] 1 [/SUP], Danwei Yu[SUP] #[/SUP][SUP] 1 [/SUP], Yang Han[SUP] #[/SUP][SUP] 2 [/SUP], Hongxia Yan[SUP] 1 [/SUP], Huihui Chong[SUP] 1 [/SUP], Lili Ren[SUP] 1 [/SUP], Jianwei Wang[SUP] 3 [/SUP], Taisheng Li[SUP] 4 [/SUP], Yuxian He[SUP] 3 [/SUP]
Affiliations
Abstract
The current COVID-19 pandemic is caused by SARS-CoV-2, a novel coronavirus genetically close to SARS-CoV, thus it is important to define the between antigenic cross-reactivity and neutralization. In this study, we first analyzed 20 convalescent serum samples collected from SARS-CoV infected individuals during the 2003 SARS outbreak. All patient sera reacted strongly with the S1 subunit and receptor-binding domain (RBD) of SARS-CoV, cross-reacted with the S ectodomain, S1, RBD, and S2 proteins of SARS-CoV-2, and neutralized both SARS-CoV and SARS-CoV-2 S protein-driven infections. Multiple panels of antisera from mice and rabbits immunized with a full-length S and RBD immunogens of SARS-CoV were also characterized, verifying the cross-reactive neutralization against SARS-CoV-2. Interestingly, we found that a palm civet SARS-CoV-derived RBD elicited more potent cross-neutralizing responses in immunized animals than the RBD from a human SARS-CoV strain, informing a strategy to develop universe vaccines against emerging CoVs.
. 2020 Oct 9;eabc9999.
doi: 10.1126/sciadv.abc9999. Online ahead of print.
Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals
Yuanmei Zhu[SUP] #[/SUP][SUP] 1 [/SUP], Danwei Yu[SUP] #[/SUP][SUP] 1 [/SUP], Yang Han[SUP] #[/SUP][SUP] 2 [/SUP], Hongxia Yan[SUP] 1 [/SUP], Huihui Chong[SUP] 1 [/SUP], Lili Ren[SUP] 1 [/SUP], Jianwei Wang[SUP] 3 [/SUP], Taisheng Li[SUP] 4 [/SUP], Yuxian He[SUP] 3 [/SUP]
Affiliations
- PMID: 33036961
- DOI: 10.1126/sciadv.abc9999
Abstract
The current COVID-19 pandemic is caused by SARS-CoV-2, a novel coronavirus genetically close to SARS-CoV, thus it is important to define the between antigenic cross-reactivity and neutralization. In this study, we first analyzed 20 convalescent serum samples collected from SARS-CoV infected individuals during the 2003 SARS outbreak. All patient sera reacted strongly with the S1 subunit and receptor-binding domain (RBD) of SARS-CoV, cross-reacted with the S ectodomain, S1, RBD, and S2 proteins of SARS-CoV-2, and neutralized both SARS-CoV and SARS-CoV-2 S protein-driven infections. Multiple panels of antisera from mice and rabbits immunized with a full-length S and RBD immunogens of SARS-CoV were also characterized, verifying the cross-reactive neutralization against SARS-CoV-2. Interestingly, we found that a palm civet SARS-CoV-derived RBD elicited more potent cross-neutralizing responses in immunized animals than the RBD from a human SARS-CoV strain, informing a strategy to develop universe vaccines against emerging CoVs.